SIGMAR1 and nephrotic syndrome: In addition, clinical examination of genetic variability (such as species, racial differences, polymorphism, and mutation), pharmacokinetic aspects (drug tissue accumulation, absorption, distribution, metabolism, and excretion), and Sigmar1 selectivity is also necessary, and clinical trials on the effects of SA4503 on nephrotic syndrome are expected to be conducted in the future.